HAE vs SRTS

Key Takeaways

• Haemonetics (HAE) is a $3.5 billion global medical technology company with diversified revenue across plasma, hospital, and blood center segments, while Sensus Healthcare (SRTS) is a $50 million micro-cap focused exclusively on superficial radiation therapy (SRT) devices for skin cancer treatment.
• HAE generated approximately $1.33 billion in revenue in its most recent fiscal year with strong free cash flow conversion; SRTS posted $27.5 million in trailing twelve-month revenue and has recently swung to operating losses amid a customer diversification transition.
• HAE benefits from an established, recurring revenue model and multiple growth drivers including the Persona PLUS platform and TEG 6s expansion; SRTS is navigating a pivotal reimbursement shift with newly issued dedicated CPT (Current Procedural Terminology) codes that could reshape its addressable market.
• Wall Street analysts rate HAE a consensus Moderate Buy with an average price target near $78, while SRTS carries a Strong Buy consensus with a $5.67 target — reflecting high upside expectations balanced against substantial execution risk.
• HAE demonstrates institutional-quality stability with 5 Buy and 3 Hold ratings; SRTS shows a binary risk-reward profile that appeals primarily to speculative investors comfortable with micro-cap volatility.
• Both companies operate in the medical device space, yet they represent fundamentally different stages of maturity, scale, and market positioning — making this comparison a study in risk-tier differentiation within healthcare.

Introduction

Investors evaluating opportunities in the medical technology sector often encounter a wide spectrum of companies — from established billion-dollar enterprises to early-stage innovators navigating transformative inflection points. This comparison examines two names at opposite ends of that spectrum: HAE (Haemonetics Corporation), a global leader in blood management and apheresis technologies, and SRTS (Sensus Healthcare, Inc.), a micro-cap developer of non-invasive skin cancer treatment systems. While both operate under the healthcare umbrella, their business models, growth trajectories, and risk profiles diverge sharply. This analysis is designed for traders and investors seeking to understand how scale, financial resilience, and market positioning shape the relative attractiveness of two medical device stocks in the current environment.

HAE Overview and Recent Performance

Haemonetics Corporation, headquartered in Boston, Massachusetts, is a global medical technology company specializing in blood and plasma component collection, surgical blood management, and interventional vascular technologies. The company operates through three primary business units: Plasma, Blood Center, and Hospital — the latter encompassing both hemostasis management (led by the TEG 6s platform) and interventional technologies including vascular closure devices.

In recent months, HAE has demonstrated notable momentum. The stock has rallied approximately 31% over the trailing three-month period, recovering from earlier-year lows and reaching levels not seen since late 2025. This upward move coincides with the company's completion of a multi-year portfolio transformation that streamlined operations toward higher-margin, faster-growing segments. Haemonetics reported full-year fiscal 2026 revenue of $1.33 billion and adjusted earnings per share (EPS) of $4.96, highlighted by record gross margins of approximately 60% and free cash flow of $210 million — an 89% conversion rate against adjusted net income.

Key catalysts supporting sentiment include FDA (Food and Drug Administration) approval of the Persona PLUS plasma collection platform, which demonstrably increases plasma yield per donation, and the acquisition of Vivasure, which expands the company's interventional technology pipeline. Management has guided for fiscal 2027 organic revenue growth of 3% to 6%, with operating margin expansion of 50 to 100 basis points. That said, Citi recently placed the stock on a "downside 90-day catalyst watch," citing elevated expectations, and the stock's P/E (price-to-earnings) ratio has expanded above 37 — near its one-year high.

SRTS Overview and Recent Performance

Sensus Healthcare, Inc., based in Boca Raton, Florida, is a medical device company focused on providing non-invasive treatments for oncological and non-oncological skin conditions using low-energy X-ray technology known as superficial radiation therapy (SRT). Its flagship products — the SRT-100, SRT-100+, and SRT-100 Vision — offer an alternative to surgery for treating non-melanoma skin cancers, including basal cell and squamous cell carcinomas, as well as keloids.

SRTS has experienced a challenging period. The stock has declined significantly from its 2024 highs, trading near $3.00 as of late July 2026 — a sharp retreat from the $5 to $9 range seen over the prior two years. First-quarter 2026 revenue was $3.4 million, down from $8.3 million in the prior-year period, as the company deliberately pivots away from dependence on a single large customer toward a more diversified base. Gross margins contracted sharply to 29.2% from 52.2% year-over-year, reflecting product mix shifts and costs associated with the company's Fair Deal Agreement (FDA) recurring revenue model.

The pivotal development for Sensus is the January 1, 2026 implementation of dedicated CPT codes for superficial radiotherapy — a regulatory milestone that increases per-fraction reimbursement by approximately 300% and, for the first time, provides clear coding specific to dermatology SRT procedures. Management describes this as transformational, and early indicators show growing inquiry levels, expanding sales pipelines, and increased physician engagement. The company also launched SensusLink, a software platform designed to generate recurring service revenue. With $18.3 million in cash and zero debt, SRTS maintains a clean balance sheet, though the path to sustainable profitability remains unproven.

Trending AI Robots

Navigating the contrasting profiles of stocks like HAE and SRTS is precisely where quantitative, data-driven tools can offer an edge. Tickeron's Trending AI Robots page showcases a curated selection of AI-powered trading bots from a library of hundreds, each designed for different trading styles, timeframes, and market conditions. These bots utilize proprietary Financial Learning Models (FLMs) that continuously adapt to real-time price action, volatility patterns, and trend signals. Performance metrics vary widely across the platform: some AI agents have posted annualized returns exceeding 100% with win rates above 65%, while others prioritize consistency with lower-risk profiles. Bots range from 5-minute high-frequency agents to 60-minute swing-trading strategies, covering everything from mega-cap indices to micro-cap equities. Only the bots best suited to current market dynamics earn placement in the Trending section. Explore the full lineup to discover which AI-driven strategies align with your trading objectives.

Head-to-Head Comparison

Scale and Business Maturity. The most immediate contrast is size: HAE's $3.5 billion market capitalization and $1.33 billion revenue base place it firmly in the mid-cap institutional category, while SRTS's sub-$50 million market cap and roughly $27 million in trailing revenue situate it in micro-cap territory. HAE serves a global customer base of plasma fractionators, blood centers, and hospitals with recurring consumables-driven revenue. SRTS relies on episodic equipment sales to dermatology practices, supplemented by an emerging recurring revenue model that remains in its early stages.

Growth Drivers. HAE's growth is anchored in plasma collection volume expansion, Persona PLUS adoption, TEG 6s consumable pull-through, and the nascent interventional technologies pipeline (including PerQseal Elite). These are diversified, multi-year catalysts. SRTS's growth thesis hinges largely on the new CPT reimbursement codes accelerating SRT adoption among dermatologists — a powerful but concentrated catalyst that remains in the proof-of-concept phase.

Financial Resilience. HAE generates substantial free cash flow ($210 million in fiscal 2026), carries manageable leverage at 2.73x net debt-to-EBITDA (earnings before interest, taxes, depreciation, and amortization), and posted a 25.4% adjusted operating margin. SRTS is currently unprofitable on a GAAP (Generally Accepted Accounting Principles) basis, with negative adjusted EBITDA of $4.2 million in Q1 2026 alone. Its $18.3 million cash position and zero-debt balance sheet provide runway but also underscore the urgency of achieving revenue scale.

Risk Factors. For HAE, key risks include plasma demand cyclicality, competitive pressure in vascular closure, integration risk from the Vivasure acquisition, and tariff-related cost headwinds. For SRTS, risks are existential in nature: customer concentration (though improving), reliance on a single product category, uncertain pace of SRT adoption even with favorable reimbursement, and the constant threat of policy reversal or competitive technological displacement.

Market Sentiment. HAE's analyst coverage reflects cautious optimism — 5 Buy ratings and 3 Holds, with price targets ranging from $62 to $90. SRTS, despite its operational challenges, commands a unanimous Buy consensus from four covering analysts, with targets between $4.50 and $6.50 — implying potential upside of 50% to 115% from current levels. This divergence illustrates how Wall Street prices HAE on execution within an established framework, while pricing SRTS on optionality around a binary reimbursement catalyst.

Tickeron AI Verdict

Based on observable trend consistency, financial stability, and relative positioning, Tickeron's AI-driven analysis would likely favor Haemonetics (HAE) in the current market environment. The stock's multi-quarter upward momentum, diversified revenue streams, strong free cash flow generation, and institutional-quality operating margins present a more probabilistically favorable setup for trend-following and stability-oriented AI models. While Sensus Healthcare (SRTS) carries a meaningfully higher theoretical upside — as reflected in analyst price targets — its elevated volatility, negative earnings trajectory, and dependence on a still-unfolding reimbursement catalyst introduce variables that AI models typically penalize in risk-adjusted frameworks. The new CPT codes represent a genuine inflection opportunity for SRTS, and AI systems with higher risk tolerance and shorter time horizons could identify tactical entry points. However, for strategies prioritizing trend consistency and fundamental stability, HAE's profile is likely to register as the stronger candidate under current conditions.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations